We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (Myeloma XI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01554852
Recruitment Status : Unknown
Verified June 2018 by University of Leeds.
Recruitment status was:  Active, not recruiting
First Posted : March 15, 2012
Last Update Posted : June 11, 2018
Sponsor:
Collaborators:
Celgene
Merck Sharp & Dohme LLC
Amgen
Information provided by (Responsible Party):
University of Leeds

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022